NBIX
HEALTHCARENeurocrine Biosciences Inc
$147.02+11.96 (+8.86%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NBIX Today?
No stock-specific AI insight has been generated for NBIX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$115.66$160.18
$147.02
Fundamentals
Market Cap$14.8B
P/E Ratio22.6
EPS$6.50
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.2%
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding100.5M
NBIX News
24 articles- Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons WhyYahoo Finance·May 7, 2026
- Is Neurocrine Biosciences (NBIX) Pricing In Too Much Caution After Recent Share Gains?Yahoo Finance·May 6, 2026
- Neurocrine Biosciences, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal HyperplasiaYahoo Finance·May 6, 2026
- Neurocrine Biosciences Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Neurocrine (NBIX) Q1 2026 Earnings TranscriptMotley Fool·May 5, 2026
- Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to SayYahoo Finance·May 5, 2026
- Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue EstimatesYahoo Finance·May 5, 2026
- Neurocrine Biosciences Reports First-Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026Yahoo Finance·May 5, 2026
- Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on EmploymentYahoo Finance·May 4, 2026
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor AgonistYahoo Finance·May 4, 2026
- Will Two-Year CRENESSITY Data in CAH Change Neurocrine Biosciences' (NBIX) Narrative?Yahoo Finance·May 2, 2026
- Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal HyperplasiaYahoo Finance·May 1, 2026
- Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult StudyYahoo Finance·May 1, 2026
- Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026GlobeNewswire Inc.·May 1, 2026
- Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to DeclineYahoo Finance·Apr 30, 2026
- Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact ScaleYahoo Finance·Apr 29, 2026
- US High Growth Tech Stocks To Watch In Your PortfolioYahoo Finance·Apr 24, 2026
- Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal HyperplasiaYahoo Finance·Apr 22, 2026
- 3 Reasons Growth Investors Will Love Neurocrine (NBIX)Yahoo Finance·Apr 21, 2026
- Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with SchizophreniaGlobeNewswire Inc.·Apr 12, 2026
- Why Soleno Therapeutics Stock Rocketed Higher on MondayThe Motley Fool·Apr 6, 2026
- Neurocrine Buys Soleno To Tap High-Growth Rare Disease MarketBenzinga·Apr 6, 2026
All 24 articles loaded
Price Data
Open$148.98
Previous Close$135.06
Day High$148.98
Day Low$141.96
52 Week High$160.18
52 Week Low$115.66
52-Week Range
$115.66$160.18
$147.02
Fundamentals
Market Cap$14.8B
P/E Ratio22.6
EPS$6.50
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.2%
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding100.5M
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—